Ferrara N - Search Results

1

Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.

Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, Berlin J, Baron A, Griffing S, Holmgren E, Ferrara N, Fyfe G, Rogers B, Ross R, Kabbinavar F. Hurwitz H, et al. Among authors: ferrara n. N Engl J Med. 2004 Jun 3;350(23):2335-42. doi: 10.1056/NEJMoa032691. N Engl J Med. 2004. PMID: 15175435 Free article. Clinical Trial.

2

Bevacizumab (Avastin), a humanized anti-VEGF monoclonal antibody for cancer therapy.

Ferrara N, Hillan KJ, Novotny W. Ferrara N, et al. Biochem Biophys Res Commun. 2005 Jul 29;333(2):328-35. doi: 10.1016/j.bbrc.2005.05.132. Biochem Biophys Res Commun. 2005. PMID: 15961063 Review.

3

Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer.

Ferrara N, Hillan KJ, Gerber HP, Novotny W. Ferrara N, et al. Nat Rev Drug Discov. 2004 May;3(5):391-400. doi: 10.1038/nrd1381. Nat Rev Drug Discov. 2004. PMID: 15136787 Review. No abstract available.

4

VEGF inhibition and renal thrombotic microangiopathy.

Eremina V, Jefferson JA, Kowalewska J, Hochster H, Haas M, Weisstuch J, Richardson C, Kopp JB, Kabir MG, Backx PH, Gerber HP, Ferrara N, Barisoni L, Alpers CE, Quaggin SE. Eremina V, et al. Among authors: ferrara n. N Engl J Med. 2008 Mar 13;358(11):1129-36. doi: 10.1056/NEJMoa0707330. N Engl J Med. 2008. PMID: 18337603 Free PMC article.

5

Pharmacology and pharmacodynamics of bevacizumab as monotherapy or in combination with cytotoxic therapy in preclinical studies.

Gerber HP, Ferrara N. Gerber HP, et al. Among authors: ferrara n. Cancer Res. 2005 Feb 1;65(3):671-80. Cancer Res. 2005. PMID: 15705858

6

VEGF regulates haematopoietic stem cell survival by an internal autocrine loop mechanism.

Gerber HP, Malik AK, Solar GP, Sherman D, Liang XH, Meng G, Hong K, Marsters JC, Ferrara N. Gerber HP, et al. Among authors: ferrara n. Nature. 2002 Jun 27;417(6892):954-8. doi: 10.1038/nature00821. Nature. 2002. PMID: 12087404

7

The biology of VEGF and its receptors.

Ferrara N, Gerber HP, LeCouter J. Ferrara N, et al. Nat Med. 2003 Jun;9(6):669-76. doi: 10.1038/nm0603-669. Nat Med. 2003. PMID: 12778165 Review.

8

Tumor refractoriness to anti-VEGF treatment is mediated by CD11b+Gr1+ myeloid cells.

Shojaei F, Wu X, Malik AK, Zhong C, Baldwin ME, Schanz S, Fuh G, Gerber HP, Ferrara N. Shojaei F, et al. Among authors: ferrara n. Nat Biotechnol. 2007 Aug;25(8):911-20. doi: 10.1038/nbt1323. Epub 2007 Jul 29. Nat Biotechnol. 2007. PMID: 17664940

9

The role of VEGF in normal and neoplastic hematopoiesis.

Gerber HP, Ferrara N. Gerber HP, et al. Among authors: ferrara n. J Mol Med (Berl). 2003 Jan;81(1):20-31. doi: 10.1007/s00109-002-0397-4. Epub 2002 Dec 14. J Mol Med (Berl). 2003. PMID: 12545246 Review.

10

Angiogenesis-independent endothelial protection of liver: role of VEGFR-1.

LeCouter J, Moritz DR, Li B, Phillips GL, Liang XH, Gerber HP, Hillan KJ, Ferrara N. LeCouter J, et al. Among authors: ferrara n. Science. 2003 Feb 7;299(5608):890-3. doi: 10.1126/science.1079562. Science. 2003. PMID: 12574630

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

670 results

Search Page